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Cervical cancer is the fourth most common malignancy in women worldwide and a
leading cause of cancer-related mortality in developing countries. Important etiological
factors in this cancer are high-risk human papillomaviruses (HPV), as roughly 96%
of cervical cancer cases are positive for these oncoviruses. On the other hand,
it has been recently pointed out that E6/E7 oncoproteins of high-risk HPV can
upregulate the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1)
axis. Likewise, several recent reports showed that checkpoint blockades targeting
PD-1/PD-L1 pathways have achieved efficient clinical responses via suppressing cancer
progression and improving survival in several types of human cancers including
metastatic cervical cancer. In this review, we summarize recent advances in our
understanding of the PD-1/PD-L1 signaling pathway and its interaction with high-risk
HPV and their oncoproteins, which could have an important impact on the management
of HPV-associated cancers including cervical.
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INTRODUCTION
The World Health Organization (WHO) categorizes cervical cancer as the fourth most common
cancer in females, accounting for 30% of cancer-mortality cases (1). In contrast, in developing
countries, cervical cancer is classified as the most frequent gynecological cancer (2). The
noted increase in disease prevalence in developing countries is partially attributed to immune-
compromising conditions including HIV, which in turn is associated with a higher risk of persistent
and multiple human papillomavirus (HPV) infections (3, 4). HPV is a non-enveloped double-
stranded DNA virus that encompasses more than 150 types. On the basis of oncogenicity, HPVs
are classified into high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 82) and low-risk
(6, 8, 11, 40, 42, 43, 44, 54, 61, 72) (5), of which high-risk HPV types 16 and 18 are the most
widespread carcinogenic strains to humans. Additionally, results from case–control studies report
a convincing association between high-risk HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66
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and carcinogenesis (5). To date, HPV, is the most common
sexually transmitted viral infection worldwide; additionally, it is
considered as the main causative agent of cervical intraepithelial
neoplasia (CIN) and cervical cancer (6, 7).
The HPV DNA genome encodes for eight proteins, of
which E5 and E6/E7 of high-risk HPV are reported oncogenes
possessing transforming characteristics (8), while E5 oncoprotein
affects cell alteration leading to carcinogenesis (9–11). More
specifically, E5 oncoprotein functions by enhancing the
expression of epidermal growth factor receptor-1 (EGFR-1)
(12) and increases phosphorylation of protein kinase B (AKT),
thereby activating the MEK/ERK1/2 pathway, thus inducing
HPV-associated carcinogenesis (13, 14). Concomitantly, Yan
et al. reported that in cervical cancer cells, inhibition of the
PI3K/Akt pathway reduces epithelial–mesenchymal transition
(EMT) as well as cellular invasion and migration, providing
a potentially valuable therapeutic target for cervical cancer
(15). On the other hand, gene transfer studies showed that
in HPV16- and HPV18-induced cervical carcinoma, E6
and E7 are the chief viral oncoproteins responsible for cell
cycle deregulation (16). The effects of E6 protein are mainly
mediated through two pathways. Firstly, E6 serves as a ligand
to p53, enhancing degradation via ubiquitin (17, 18). In
healthy individuals or in HPV-negative cells, degradation of
p53 is mediated through the ubiquitin–proteasome system
(19). Secondly, E6 triggers telomerase activity contributing
to the uncontrolled proliferative capacity of cancerous cells
(20). Equally, E7 oncoprotein exerts its action by binding to
several members of the retinoblastoma (Rb) family of tumor
suppressor proteins, mainly hypo-phosphorylated form of pRb,
resulting in destabilization of the Rb/E2F complex, which in
turn leads to an increase in gene transcription and initiate cell
proliferation (21).
On the other hand, immune checkpoints are essential
mechanisms that function under physiological conditions
averting autoimmunity and minimizing allergic reactions (22).
Programmed cell death-1 (PD-1) is a type I transmembrane
protein receptor that upon interacting with its ligands, PD-
L1, and PD-L2, triggers a cascade of downstream signals
and suppresses T cell activation (23). Since CD8+ T cells
play a vital role in eliminating cancer cells, their inhibition
interferes with cancer eradication and permits its immune
escape (24). In cervical cancer, multiple studies have emphasized
on the independent role of the PD-/PD-L1 pathway in
cancerous cell proliferation and growth (25, 26) and the
involvement of E5 and E6/E7 oncoproteins in the pathogenesis
of cervical cancers (27, 28). However, the interrelation
between high-risk HPV oncoproteins (E5, E6/E7) and PD-
1/PD-L1 pathways and their potential synergic effect are
yet to be fully elucidated. Furthermore, identification of
potential therapeutic options designed to target HPV-PD-
1/PD-L1 interaction in cervical cancers and CIN is essential
given the prominence of HPV infections in this type of
cancers. This review aims to underline the interrelation
between high-risk HPV oncoproteins and PD-1/PD-L1 in
the pathogenesis of cervical cancer, which could reinforce the
role of PD-1/PD-L1 inhibitors as one of the main therapies
for the management of HPV-positive human carcinomas
including cervical.
PD-1 AND PD-L1 PATHWAY
As we mentioned above, the role of high-risk HPV in cervical
carcinogenesis is well-established and documented (29, 30). On
the other hand, the emergence of immunotherapy coupled with
the exponential increase in understanding therapy-induced host
immune response in hindering tumor proliferation played a
pivotal role in the identification of novel immune checkpoint
inhibitors for treatment of several types of cancers (25, 31, 32).
In physiological conditions, immune checkpoints are thought to
be essential in regulating the immune system, thereby preventing
the development of autoimmune diseases (33). In this context,
the PD-1 receptor is thought to be an immune checkpoint
mediator, subduing tumor-induced immunity (34).
In healthy individuals, the PD-1 pathway regulates antigen-
mediated inflammatory response to ensure minimal damage to
healthy tissues (35). Notably, in the presence of a recognizable
antigen expressed by the major histocompatibility complex
(MHC), an inflammatory response is triggered through the
activation of T cells and recruitment of cytokine-producing
cells (34). Immune tolerance is elicited following cytokine-
induced PD-L1 expression in tissues and the activation of PD-1
protein on T-cells (34). Once activated, the PD-1/PD-L1 pathway
inhibits T-cell receptor (TCR) signal transduction and CD28–
CD8 co-stimulation, thus hindering T cell activity (36). On the
other side of the spectrum, toll-like receptors (TLR) function
through sensing common pathogen features and activating
innate immunity. Drug-induced activation of TLR9 was proven
to moderately improve immunogenic tumor sensitivity and
augment innate immunity to promote tumor regression, thus
indicating plausible potential synergetic effects between TLR9
agonist and PD-1 inhibitors (37).
PD-1 CHECKPOINTS AND CERVICAL
CANCER
Several studies showed an elevation of PD-L1 in a variety of
cancers, including cervical. Immunohistochemistry studies were
used to determine PD-L1 expression, and the staining intensity
was used to quantify the levels of PD-L1 in tumor sections
(38, 39). Elevated PD-L1 expression inhibits T cell activity
and thereby favors a state of immune resistance (40). Further,
a direct correlation between PD-L1 overexpression and poor
overall survival in patients with cervical cancer was reported (41).
Markedly,Wang et al. reported an overexpression of PD-L1 levels
in CIN 1–2 lesions (20/21 = 95%) as opposed to histologically
normal cervical epithelia (0/55) (42). On a similar note, Meng
et al. and Feng et al., respectively, reported an overexpression of
PD-L1 in more than 60% (59/97) and 45% (31/66) of patients
with cervical cancer (39, 43). Additionally, PD-L1 expression
was found in 34.4–96% of cervical carcinomas as opposed to
histologically normal cervical tissues in which PD-L1 expression
was minute (26, 44, 45). Similarly, Reddy et al. reported
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an increase in PD-L1 expression by 29% in adenosquamous
carcinomas, 17% in endocervical carcinomas, and 38% in
squamous cell carcinomas (SCCs) (46). Furthermore, Heeren
et al. found a higher abundance of PD-L1-positive immune
cells in close proximity to metastatic tumors as compared with
paired primary tumors. The quantification was done based on
the presence or absence of PD-L1-positive tumor-infiltrating
cells as well as the accumulation of immune cells around
tumor fields forming a PD-L1-positive cordon. Additionally, the
authors reported PD-L1-positive tumor-associated macrophages,
expressing CD163, and/or CD14 (47). This implies the important
role that PD-1/PD-L1 axis plays in hindering immunity against
cervical cancer. Remarkably, upregulated levels of PD-L1 in
SCCs are associated with poorer disease-free and disease-specific
survival rates in comparison to those with normal or minute
PD-L1 levels (47). Moreover, presence of PD-L1-positive tumor-
associated macrophages correlates with worst disease-specific
survival rates in adenocarcinoma patients (47). Evidently, the
PD-1/PD-L1 pathway plays an important role in the pathogenesis
of cervical cancer.
The illustrated PD-1 mechanism of action and the role it plays
in the pathogenesis of a variety of cancers coupled with its unique
structure—resembling that of cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4) but with a unique ligand specificity and
biological functionality—makes it an exceptional drug target
(48). Unlike CTLA-4 ligands, earlier studies pointed out that PD-
1 ligands are selectively expressed in various cancers as well as
within tumor microenvironments (49, 50); specifically, PD-1 was
found to be quite prominent in various solid and hematological
malignancies (49–54). An in vitro study by Fife et al. revealed
that antibody-mediated inhibition of PD-L1 binding to PD-1
resulted in lower T cell motility and enhanced T cell-dendritic cell
interaction (55). Together, these findings support the use of PD-1
inhibitors as a promising strategy for tumor immunotherapy.
Understanding the pathways through which PD-L1
checkpoint activation leads to the development and progression
of solid tumors provides a path to investigate the effects of
PD-L1 inhibitors on solid tumor regression. Phase 3 clinical
trials revealed a statistically significant increase in overall
survival in myeloma patients receiving nivolumab (PD-L1
inhibitor) with 73% overall survival as compared to 42% for
those who received dacarbazine (standard treatment) (56).
Administration of various doses of pembrolizumab in patients
with recurrent metastatic cervical cancer showed an overall
response rate (ORR) of 14.33–17% (57, 58). Similarly, in
patients with recurrent or metastatic HPV-related cancers (19
cervical and five vaginal/vulvar carcinomas, CheckMate358
study, NCT02488759), administration of nivolumab showed
an ORR of 26% in patients with cervical cancer (59). Notably,
the response to nivolumab was unrelated to PD-L1 status or
previous treatments. Thus, the use of PD-1 inhibitors for cervical
cancer is a promising treatment strategy.
In this context, pembrolizumab, an immune checkpoint
inhibitor, represents a full-length human IgG4/kappa
monoclonal antibody that is directed against the PD-1 protein
(60, 61) and has been approved by the FDA as a second-
line treatment for recurrent or metastatic carcinomas of the
cervix, non-small cell lung, and urothelial as well as malignant
melanoma (60). Pembrolizumab (Keytruda) was approved for the
treatment of patients with recurrent and/or metastatic cervical
cancer in 2018 based on the KEYNOTE 158 (NCT02628067)
Phase II study which involved 98 patients with recurrent and/or
metastatic cervical carcinomas (62). The objective response rate
(ORR) among 77 patients was achieved in 14.3% including 2.6%
complete responses and 11.7% patients having partial responses
(62). Of note, the FDA also concurrently approved the PD-L1
immunohistochemistry 22C3 pharmDx test (Dako Agilent)
as a companion diagnostic test to guide the patient selection
process for pembrolizumab treatment (63). This is critically
important since pembrolizumab as a single agent exhibits a
limited efficacy in recurrent and/or metastatic setting in an
unselected patient population (61). Moreover, an ongoing phase
III trial (KEYNOTE-826 phase III trial, NCT03635567) aims to
treat advanced or recurrent cervical cancer in the first line using
pembrolizumab or a placebo plus one of four platinum- and
taxane-based chemotherapy regimens (61). Notably, patients are
being stratified based on PD-L1 expression (combined positive
score ≥1) by immunohistochemistry (62, 63).
Given that clinical benefits of pembrolizumab in cervical
cancer are still sparse and limited, there is an unmet need for
more trials and studies that explore the role of pembrolizumab
in addition to other immune checkpoint inhibitors (e.g., PD-
1 (nivolumab and cemiplimab) and PD-L1 inhibitors (e.g.,
durvalumab, avelumab, and atezolizumab) (64). A combinatorial
approach with immune checkpoint inhibitors is also warranted
(65). This is particularly important given that immune
suppression (impaired cellular response) caused by the activation
of the inhibitory axis PD-1/PD-L1 strongly favors persistent HPV
infections, viral integrations into the cervical epithelium, and
concomitant expression of the key viral oncoproteins such as
E6 and E7 proteins (64). In addition, a combined treatment of
immune checkpoint inhibitors with other therapeutic modalities
(e.g., bevacizumab, conventional chemotherapy, radiotherapy) is
also a huge challenge.
HPV ONCOPROTEINS AND PD-1/PD-L1
INTERACTION IN CERVICAL CANCER
In the case of cervical cancer, high-risk HPVs are a determining
factor in its pathogenesis; continual HPV infection is associated
with pathogenesis of cervical cancer and is correlated with its
prognosis. This, coupled with the significance of the PD-1/PD-L1
axis in cervical cancer etiology, has made it crucial to investigate
the interrelation between E5 and E6/E7 oncoproteins and the
PD-1/PD-L1 pathway in the pathogenesis of cervical cancer
(Figure 1). Research has shown a significant association between
HPV positivity and enhanced PD-L1 expression (9, 42, 66).While
studies highlighting the association between E5 oncoprotein of
high-risk HPV and PD-1/PD-L1 expression in cervical cancer
are scarce, Kim et al. investigated the effects of E5 expression
on epidermal growth factor receptor-1 (EGFR1) and vascular
endothelial growth factor (VEGF) in cervical cancer cell lines
(12), concluding that E5 oncoprotein activates EGFR1 thereby
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FIGURE 1 | Schematic outline showing the potential interaction between E5, E6, and E7 of high-risk HPV oncoproteins with their intermediate proteins as well as their
signaling pathways which can deregulate PD-1 and PD-L1 expression patterns, consequently leading to compromised immunity.
upregulating the expression of VEGF (9). Furthermore, HPV16-
E6 binds to Na+/H+ exchanger regulatory factor-1 (NHERF-1)
and results in the breakdown of NHERF-1 via the proteasome
pathway (67). Also, E7 combines with E6 to underpin NHERF-
1 degradation, thus triggering the PI3K/AKT pathway (68).
Moreover, in vitro data link loss of NHERF-1 in cervical cancer
with increase in cellular growth, proliferation, cell cycle, and
ERK signaling stimulated by EGFR (69, 70). Incessant EGFR
activation by NHERF-1 correlates with poor prognosis in cervical
cancer (70). Also, NHERF-1 has been found to play a role in
cisplatin resistance of cervical cancer cells by inhibiting AKT
and ERK signaling pathways (71). Moreover, loss of NHERF-1
expression in the cervical cell line promoted cellular adhesion,
wound healing, and invasion, indicating NHERF-1 as a plausible
therapeutic target for cervical cancer patients (72). Similarly,
He et al. report that EGFR activation increases the expression
of yes-associated protein (YAP), thus inducing cervical cancer
cell proliferation and migration (73). More importantly, Chen
et al. investigated the effects of EGFR1 on PD-L1 activity in
NSCLC (74). This study found that EGFR1 activation induces
PD-L1 expression through the phosphorylation of ERK1/2/c-
Jun, potentially causing T cell apoptosis. On the other hand,
Lee et al. analyzed the role YAP plays in the activation of
the PD-1/PD-L1 pathway (75). The study concluded that YAP
regulates the transcription of PD-L1; thus, targeting PD-L1 either
directly or through YAP could be a potential therapeutic target
(75). Yang et al. showed a correlation between increased PD-
1 expression on T cells and persistent high-risk HPV infection
with the development of cervical intraepithelial neoplasia (CIN)
(44). Altogether, E5 oncoprotein activates EGFR, which enhances
YAP leading to the upregulation of PD-L1, thus initiating T cell
apoptosis and persistent HPV infections and augmenting the
risk of cervical cancer development (44, 73, 75). MicroRNAs
(miRs), a class of small regulatory, non-coding RNA molecules,
play a vital role in gene expression modulation and regulating
major pathways (76). High-risk HPV oncoproteins interact with
miRs to regulate the onset and progression of cervical cancer
(77). One such miR, miR-34a, is directly regulated by p53 and
targets molecules regulating cell proliferation, cellular apoptosis,
G1 arrest, DNA repair, and senescence (78–81). HPV-E6 blocks
miR-34a expression via the p53 pathway inducing virus-infected
cell survival and cancer cell proliferation and metastasis (82, 83).
A study by Li et al. (81) showed loss of miR-34a expression in
precancerous cervical lesions, indicating this as an early-onset
event in cervical cancer development (81). Several studies have
shown reduced miR-34a expression in both cervical cancer cells
and tissues associated with invasive carcinomas (81, 82, 84–86).
Moreover, Cortez et al. (87) and Wang et al. (88) analyzed the
role of miR-24a in controlling PD-L1 activity (87). In vitro and in
vivo data showed that p53 regulates PD-L1 via miR-34a (87, 88).
miR-34a directly attaches to the PD-L1 3
′
-untranslated region,
inhibiting PD-L1; thus, induction of miR-34a resulted in reduced
PD-L1-specific T cell apoptosis, indicating that tumor immune
evasion is regulated by the p53/miR-34a/PDL1 axis (87, 88).
Expression of another miR, miR-200c, was lost in cervical cancer
tissue samples and cell lines (89). Elevated p53 levels inhibit miR-
200c levels and correlate with increased cervical cell invasion,
migration, and proliferation abilities (90, 91). Further, miR-200c
expression is significantly reduced in PD-L1-positive samples,
suggestingmiR-200c as a potential regulator of PD-L1 (92). Thus,
increased PD-L1 expression can elevate miR-200c expression,
inhibiting tumor cell migration, and metastasis (93).
Moreover, a study by Liu et al. investigated the mechanisms
underlying HPV-induced evasion of cervical cancer cells
from the host immune system via the PD-L1/PD-1 signaling
pathway (66). Quantification of HPV16-E7 expression using
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immunohistochemistry and RT-PCR analyses revealed low levels
of HPV16-E7 in normal tissues in comparison to elevated
levels detected in cervical cancer tissues; immunohistochemical
analysis showed strong PD-L1 expression in cervical cancer
samples (P = 0.017) (66). A statistically significant (P = 0.043)
positive correlation between HPV16-E7 and PD-L1 protein
expression in cervical cancer tissues was reported, indicating that
HPV16-E7 potentially downregulates lymphocyte proliferation
by stimulating the PD-L1 pathway and weakening the immune
response to tumor cells (66). Also, the association of HPV-E7 to
pRb results in the degradation of the cell cycle allowing cells to
undergo unchecked proliferation (94, 95). E7 also binds to and
inhibits the IκB complex, thus reducing the levels of NFκB (96).
HPV16-E6 and E7 proteins repress basal and TNF-α-inducible
NF-kB activity in cervical cancer cells, promoting onset of
cervical cancer (97). Loss of NF-kB allows the virus to restrict the
host immune response and stimulates continuous HPV infection
which can in turn trigger clonal growth and immortalization
of cervical epithelial cells (97). Furthermore, PD-L1 expression
is regulated by NF-κB during EMT signaling; NF-κB activates
PD-L1, promoting cancer growth, and progression (98). Herein
it is important to highlight that the interaction between PD-
L1 and HPV oncoproteins could be specific to only certain
types of high-risk HPVs or coinfection with more than one
type since more than 96% of human cervical cancers are
positive for HPVs, while around 40% of these cancer cases
overexpress PD-L1, as reported by Meng et al. (39) and Feng
et al. (43).
Furthermore, numerous studies investigated the role of PD-L1
expression in the prognosis and therapeutic efficacy of cervical
cancer patients. Yang et al. explored the correlation between the
modulation of the PD-1/PD-L1 axis and CIN grading of cervical
cells in high-risk HPV (–) and (+) women (44). In patients
with high-risk HPV, ELISA revealed a reduced expression of
Th1 cytokines, interferon-c (IFN-c), and interleukin-12 (IL-
12). In contrast, Th2-type cytokine and interleukin-10 (IL-10)
were increased as compared with high-risk (–) HPV. High-
risk HPV positivity correlated with increasing CIN grade.
As for the PD-1/PD-L1 axis, Yang et al. showed that the
activation of the PD-1/PD-L1 pathway suppresses cell-mediated
immunity (CMI), by inhibiting pro-inflammatory cytokines
and upregulating anti-inflammatory cytokines, thus leading to
localized immunosuppression and high-risk HPV-induced CIN
progression (44) (Figure 1). A study by Qin et al. (99) showed
that HPV-induced somatic mutations played a vital role in
the inhibitory tumor microenvironment resulting in aberrant
expression of checkpoint-related genes (CTLA-4, PD-1, and PD-
L1) (99). Furthermore, the expression of HPV oncoprotein-
associated master regulators was determined and their effect
on the functionality of the immune system in cervical cancer
was analyzed (99); thus, a positive correlation (p < 0.001)
was reported between certain HPV-induced master regulators,
specifically ENO1, FOSB, PA2G4, SOX9, TEAD4, FOXO4, and
MNT, in cervical cancer samples (n = 306) in comparison
with normal cervix (n = 11) tissue obtained from The Cancer
Genome Atlas (TCGA). This proposes the induction of an
immune-deficient state caused by the HPVE6/E7 expression that
is mediated through a variety of pathways including the PD-
1/PD-L1 axis (99). In summary, a positive correlation between
HPV E5, E6, and E7 oncoproteins and enhanced PD-1/PD-
L1 expression has been reported with tumor metastasis (22),
tumor progression (100), and poor prognosis (47) in cervical
cancer. However, the exact underlying mechanism by which
these two elements are interconnected still remains nascent.
Studies suggest that E6/E7 activates the PD-1/PD-L1 axis causing
an increase in Th2-type cytokine and IL-10 expression and a
decrease in Th1 cytokine IFN-c and IL-12 expression leading to
immunosuppression and further progression of CIN (101, 102)
(Figure 1).
To identify therapeutic targets for local immune modulation,
multiparameter flow cytometric T-cell profiling of primary
cervical tumors (PT) and tumor-draining lymph nodes (TDLN)
of cervical cancer was performed (103). The study reported
that the inhibition of PD-1 led to a significant increase in
E6-specific T-cell responses in 80% of HPV16+ TDLN and
in 20% of HPV16+ PT as well as enhanced expression levels
of CD8+, FoxP3+, and CD25+ T cells, thus confirming
its efficacy (103). Taking into account the promising results
reported from PD-1/PD-L1 inhibitors in the treatment of
high-risk HPV-mediated cervical cancers (104), the efforts are
now directed toward combination therapy with PD-1 pathway
blockers and E6/E7-targeted therapy. Effects of CRISPR/Cas9
to target both HPV and PD-1 in vitro and in vivo models
(104) were tested, and results showed that the combination
therapy with gRNA-PD-1 and gRNA-HPV16 E6/E7 significantly
reduced tumor growth and enhanced survival. Moreover, an
increase in the population of dendritic cells, CD8+, and CD4+
T lymphocyte was observed following the administration of
the combination therapy (104). Ongoing clinical trials are
investigating the use of various PD-1 inhibitors/modulators
[nivolumab (105), atezolizumab (106), and pembrolizumab
(107)] in combination with concurrent chemoradiation therapy
(CCRT) for the management of advanced and recurrent cervical
cancers. Additionally, promising results from a phase II clinical
trial investigating the effects of combined immune checkpoint
inhibitor and tumor-specific vaccine (ISA 101, a synthetic long-
peptide HPV-16 vaccine) for patients with incurable HPV-16-
induced cancer was obtained (108).
These investigations show that PD-1/PD-L1 inhibitors could
be in fact promising therapeutic targets for HPV-associated
cancers, especially cervical. Although studies analyzing the
potency of PD-1/PD-L1 inhibitors in the management of cervical
cancer are rare, there are few studies on the clinical application
of PD-1/PD-L1 inhibitors and/or new inhibitors targeting other
elements of cell death program. Given the promising results of
these preliminary studies, we believe more investigations are
necessary to elucidate the role and efficacy of such treatments.
The major limitations in studies conducted thus far include
lack of data regarding overall survival, drug resistance, and the
underlying mechanisms. Such data can aid in selecting patients
for cell death program inhibitors, including PD-1/PD-L1, and
pave the way for new therapeutic interventions. On the other
hand, it is important to highlight that PD-1/PD-L1 inhibitors
have proven to be a viable therapy that can reactivate immune
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response against cancerous cells and favor apoptosis as opposed
to tumor growth and proliferation. Moreover, current clinical
trials investigating the use of cell death program inhibitors,
including PD-1/PD-L1, for the treatment of cervical cancer
are limited to advanced, persistent, and metastatic cancers.
Therefore, it would be interesting to investigate the effectiveness
of these agents on early-stage cervical cancers in a small cohort.
Additionally, the promising outcomes noted in combination
therapy of PD-1 inhibitors with other treatment modalities in
various types of cancers favor combination therapy as opposed
to PD-1 inhibitor monotherapy for cervical cancer management.
CONCLUSION
It is known that the majority of human cervical cancers
are positive for high-risk HPVs that involve three known
oncoproteins, E5, E6, and E7, which regulate cell-cycle and
tumor-suppressor genes, thereby affecting apoptosis and cell
death program. We have reviewed the cross talk between high-
risk HPV oncoproteins and the PD-1/PD-L1 pathway in the
pathogenesis of cervical cancer. It is evident that there is a strong
interplay between oncoproteins of high-risk HPV and cell death,
including PD-1 activation, as reported in several investigations.
More specifically, HPV oncoproteins E5 and E6/E7 can activate
the PD-1/PD-L1 axis; hence, further research is required to
elucidate the association between HPV status and the efficacy
of PD-1/PD-L1 inhibitors and/or other inhibitors related to cell
death program in cervical cancer. On the other hand, analyzing
the interaction between oncoproteins of high-risk HPVs and
cell death program including PD-1/PD-L1 can also help in
identifying candidate novel biomarkers that can help in the
prognosis of cervical cancer patients.
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